<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Contact urticaria and related conditions</dc:title><dc:creator>Bizjak,	Mojca	(Avtor)
	</dc:creator><dc:creator>Košnik,	Mitja	(Avtor)
	</dc:creator><dc:subject>inducible urticaria</dc:subject><dc:subject>occupational urticaria</dc:subject><dc:subject>protein contact dermatitis</dc:subject><dc:subject>urticaria</dc:subject><dc:subject>anaphylaxis</dc:subject><dc:subject>histamine antagonists</dc:subject><dc:subject>epinephrine</dc:subject><dc:subject>contact dermatitis</dc:subject><dc:subject>contact urticaria</dc:subject><dc:description>Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non-immunologic (NI-CoU) and immunologic (I-CoU) types, with I-CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the CoU syndrome. Patients with I-CoU may also have other type I (immediate) allergic diseases, such as allergic conjunctivitis, rhinitis, asthma or food allergy. This review provides a detailed overview of CoU and related conditions, focusing on triggers, diagnostic methods and management strategies. NI-CoU is typically triggered by low molecular weight chemicals, while I-CoU involves IgE-mediated hypersensitivity to both high molecular weight proteins and low molecular weight chemicals. Early diagnosis is crucial, though CoU is often underrecognized. The diagnostic approach includes a thorough medical history, physical examination, evaluation of photographs, (non)invasive skin tests and in vitro assessments. Management strategies prioritise trigger avoidance and pharmacological treatments when avoidance is not fully possible. For I-CoU, second-generation H1-antihistamines are the first-line treatment. Severe cases of I-CoU may benefit from anti-IgE therapy (omalizumab). Patients at risk of anaphylaxis should carry an adrenaline auto-injector and wear a medical alert bracelet.</dc:description><dc:date>2025</dc:date><dc:date>2025-12-09 10:17:26</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>176687</dc:identifier><dc:identifier>UDK: 616.5-002:616.97</dc:identifier><dc:identifier>ISSN pri članku: 1600-0536</dc:identifier><dc:identifier>DOI: 10.1111/cod.14794</dc:identifier><dc:identifier>COBISS_ID: 232153859</dc:identifier><dc:language>sl</dc:language></metadata>
